Kornimate/medical-research-clean huggingface dataset:
central and peripheral venous catheters associated blood stream infection in icu in assiut university

Conditions: Blood Stream Infection

Summary: catheter related infections (cris) were found to be associated with several risk factors, including patient related risk factors such as age, gender, clinical status and catheter related risk factors such as the vascular access location, dwelling time, catheter type and number of lumens. in addition to the inserted solution type and the experience of the professional who performs the procedure ,these factors constitute important strategic points for actions to compare the infectious complications of peripheral versus central venous catheters in critically ill patients.

nosocomial (hospital-acquired) bloodstream infections (bsis) are an important cause of morbidity and mortality, with an estimated 250,000 cases occurring each year in the united states. bsis may be either primary or secondary. secondary infections are related to infections at other sites, such as the urinary tract, lung, postoperative wounds, and skin. most nosocomial bsis are primary, as illustrated by the united states centers for disease control and prevention's national nosocomial infection surveillance system, in which 64 percent of the nosocomial bsis reported were primary bsis. while some primary bsis have no identifiable source, most are associated with intravascular catheters, and central venous catheters (cvcs) in particular. critically ill patients require intravenous administration of fluids and drugs.this can be achieved via peripheral or central catheters. each device is associated with both mechanical and infectious complications. complications associated with central lines are judged to be more severe. some patients actually require the insertion of a central line due to the venous toxicity of the drugs or to the necessity of making sure that the infusion is regularly administered (example: high dose catecholamine infusion). some physicians believe that most intensive care unit (icu) patients should have a central venous line inserted, whereas others feel that some patients may receive active drugs via a peripheral line in selected instances. endpoints are the rate of mechanical complications (difficulty in inserting the line, need for repeat insertion attempts, occurrence of arterial puncture, occurrence of pneumothorax) and of infectious complications (local catheter infection or catheter-related bloodstream infection).

Eligibility criteria:
inclusion criteria: * all patient at icu diagnosed nosocomial infection exclusion criteria: * patients exist already infected before admission at hospital.
pilot study of virtual reality for providing exposure therapy to children

Conditions: Generalized Anxiety Disorder

Summary: drs. from the mayo clinic rochester will plan and execute a feasibility study of the phase i prototype version of the virtual reality exposure therapy system. dr. x, who has significant experience in evaluating patient experiences and opinions of technologies intended to change behavior, will oversee a qualitative study to examine the prototype system. twenty children with generalized anxiety disorder with perfectionism who have received less than 3 treatment sessions and a parent will be recruited to pilot the virtual reality system.

twenty children with generalized anxiety disorder (perfectionism) who have received less than 3 treatment sessions and a parent will be recruited to pilot the virtual reality system. participants will be identified through the mayo clinic pediatric anxiety disorders clinic (padc) using purposive sampling methods. each patient will participate in a single (up to) 2-hour visit, allowing for breaks as needed. staff from mayo clinic healthcare policy \& research experienced in qualitative data analysis and not involved with the patients' medical care or development of the prototype system will conduct the study visits. during the first 30 minutes the patient and parent will be introduced to the virtual reality system and the rationale for this feasibility study. next, a therapist from the padc, all of whom are experienced exposure therapists, will lead the patient through exposure exercises using the virtual reality system for up to 30 minutes. during the next period, up to 30 minutes, the therapist will go to a different room and the patient, with support from their parent, will complete exposure exercises using the virtual reality system that the therapist directed them to complete. during the exposures the interviewer will observe, code and record the patient's interaction with the virtual reality system. the data from the virtual reality system will be automatically transmitted to a cloud service running on a local laptop to study the effectiveness of the system's automatic logging capabilities. for the remaining time (up to 30 minutes) the interviewer will interview the patient about his or her experience with the virtual reality system and then will ask for observations and opinions from the parent.

Eligibility criteria:
inclusion criteria: * diagnosis of generalized anxiety disorder with perfectionism and have received less than three treatment sessions exclusion criteria: * too young to safely and effectively participate with the study materials
a study of amdx-2011p in participants with primary open angle glaucoma

Conditions: Primary Open Angle Glaucoma

Summary: the purpose of this research study is to assess the ability of amdx- 2011p to identify amyloid deposits in the retina of participants with primary open angle glaucoma (poag).

this open-label, masked endpoint assessment study will evaluate safety, tolerability, plasma pharmacokinetics (pk) and biological activity of intravenous (iv) doses of amdx-2011p in participants with poag. assessments of retinal images will be conducted by centrally masked assessors. participants will be admitted to the study site where eye examination and retinal imaging will be conducted before administration of the study drug. amdx-2011p will be administered through a single iv bolus injection followed by safety assessments, retinal imaging, and blood collection and pk.

Eligibility criteria:
inclusion criteria: 1. diagnosis of primary open angle glaucoma in both eyes 2. able to fixate 3. glaucomatous optic nerve damage in both eyes, as determined by an investigator as part of an eye exam exclusion criteria: 1. participants unable to read or write 2. ocular media is not sufficiently clear to obtain acceptable quality images 3. participants with presence of any ocular pathology other than glaucoma in the study eye (cataracts are acceptable)

Keywords: poag
application of the triple stimulation technique to patients with cns disorders including stroke

Conditions: Stroke Patients

Summary: tst (triple stimulation technique) helps to better quantify the proportion of motor units activated by transcranial magnetic stimulation. the abnormal amplitude registered by tst is proportional to the intensity of conduction disorders. the evaluation of these disorders is more precise with this technique than with the slowing of the central conduction time (cct). the investigators propose to use this technique in cns pathologies where this disorder is significant and essential, like multiple sclerosis and stroke.


Eligibility criteria:
inclusion criteria: * stroke patients with hemiparesia exclusion criteria: * pace maker * epilepsia * metallic neurosurgical implants

Keywords: tst tms stroke patients emg
control of periodontal infections

Conditions: Periodontitis

Summary: the purpose of this study is to test combined effects of scaling and root planing with periodontal surgery, systemically administered amoxicillin and metronidazole, and/or local tetracycline on pocket depth reduction and attachment level "gain" in patients with chronic periodontitis.

in this 2x2x2 factorial design study, 229 moderate to advanced chronic periodontitis patients stratified according to current smoking status were recruited in usa and sweden. patients were randomly assigned to 8 groups, all of which were treated by srp plus none, one, two or three adjunctive treatments. thus, patients were assigned to groups that did or did not receive surg, lab, sab or lab+sab (all) providing 8 treatment combinations (surg + all, surg + sab, surg + lab, surg alone, srp + all, srp + sab, srp + lab, srp alone). clinical, microbiological and immunological measurements were taken for 2 years (at baseline, 3, 6, 12, 18 and 24 months). to focus on changes diseased sites, analysis was restricted to sites with baseline pocket depth greater than 5 mm. (also, these were the only sites treated by lab). in this report, main effects and interactions were evaluated for pd reduction and al gain two years post therapy for 187 of patients. mean values were computed for each treatment group and averages after 2 years were compared to baseline by anova. factorial ancova was used to examine significance of differences between surg or not, sab or not and lab or not for pd reduction and al gain using baseline attachment level or pocket depth as covariates and including current smoking as a factor.

Eligibility criteria:
inclusion criteria: * greater than 20 years of age * had a least 15 natural teeth * in good general health * at least 4 teeth with pockets \> 6 mm * at least 8 teeth with al \> 3 mm at baseline exclusion criteria: * pregnant or nursing (if female) * having antibiotic or periodontal therapy in the previous three months * systemic conditions that would affect the course of periodontal disease * systemic conditions that required antibiotic coverage * allergic to drugs used in the study

Keywords: amoxicillin antibiotics chronic periodontitis local drug delivery metronidazol randomized controlled trial subgingival scaling surgery tetracycline moderate to advanced chronic periodontitis
a phase ii study in patients with moderate to severe active crohn's disease

Conditions: Crohn's Disease

Summary: the proposed study is a randomized, double-blind, placebo-controlled, multi-center phase ii study to investigate the safety and efficacy of shr0302 in patients with moderate to severe active crohn's disease. the study aims to evaluate the optimal dose of shr0302 and time needed in inducing clinical remission in active cd. this is an 12+12 weeks study, in which participants who complete the first 12 weeks treatment phase, will have the option to enter a blinded active arms 12-week extension phase. early withdrawn subjects during the first treatment phase cannot enter the extension phase. the total duration of the study participation, including extension and follow-up, will be approximately 26 weeks. with the wealth of scientific evidence on jak/stat involvement in ibd, the data from similar class of new drugs and the current data on shr0302 (jak1 inhibitor), support the rationale to proceed with phase ii studies to evaluate the efficacy and safety of shr0302 in patients with moderate to severe active cd.


Eligibility criteria:
inclusion criteria: * male and female subject at ≥18 and ≤ 75 years of age at randomization. * subjects with a documented three-month history of diagnosed ileal, colonic, or ileocolonic crohn's disease at the time of randomization. * currently having crohn's disease with crohn's disease activity index (cdai) score ≥ 220 to ≤450. exclusion criteria: * diagnosis of indeterminate colitis, or clinical findings suggestive of ulcerative colitis. * subject with cd with stoma, gastric or ileoanal pouch, proto-colectomy or total colectomy, symptomatic stenosis or stricture, history of bowel perforation, suspected abscess; actively draining fistula. * treatment naïve subjects diagnosed with crohn's disease, (without previous exposure to treatment).
effects of the face mask on physical fitness in children

Conditions: Physical Fitness; Health; Childhood ALL; Emotional Stress; Sedentary Behavior; Cardiorespiratory Fitness

Summary: the aim of this multicenter randomized crossover design study is to evaluate a sample of 500 boys and girls from public and private schools in the principality of asturias, aged between 6 and 12 years, with the objective of determining the level of physical condition, as well as to evaluate the effect of the use of ffp2/n95 face masks during the execution of the alpha fitness battery, and the emotional effects caused by the use of these masks. this is a sample obtained by accessibility, in which the sampling will be stratified by age and academic year.


Eligibility criteria:
inclusion criteria: 1. age between 6 and 12 years old. 2. be able to perform all the tests and procedures that comprise the study. 3. have signed informed parental consent. exclusion criteria: 1. to take drugs that can affect the measurements 2. contraindications or pathologies associated with exercise

Keywords: exercise alpha fitness battery kids n95/ffp2 physical activity cdi
replicor compassionate access program

Conditions: Viral Hepatitis B; Viral Hepatitis D; Cirrhosis, Liver; Decompensated Cirrhosis; Ascites Hepatic; Varices, Esophageal; Hepatocellular Carcinoma

Summary: the goal of this compassionate access program is to provide early access to rep 2139-mg for patients with hbv mono-infection or hbv / hdv co-infection who either have advanced (decompensated) cirrhosis or who have failed to response to other other antiviral agents either approved or under development and who are in danger of progressing to decompensated cirrhosis. this compassionate access program will provide access to a once weekly regimen of subcutaneously (sc) administered rep 2139-mg for a period of 48 weeks with the goal of achieving functional cure of hdv and or hbv, with the reversal of liver disease in the absence of antiviral therapy. the safety, tolerability and efficacy of sc rep 2139-mg will be monitored during and after therapy

nucleic acid polymers (naps) block the assembly of hepatitis b virus (hbv) subviral particles and bind to the small and large hepatitis delta virus (hdv) antigen. in chronic hbv mono-infection, this leads to rapid hbsag loss and in chronic hbv / hdv co-infection, simultaneous loss of hbsag and hdv rna. nap-based combination therapy (using rep 2139-mg) achieves high rates of functional cure of hbv and hdv in the absence of therapy in previous clinical trials limited to patients without cirrhosis. the replicor compassionate access program (rcap) provides early access to individuals which have hbv mono-infection, or hbv / hdv co-infection who have not responded to existing approved or experimental therapies and are in danger of progressing advanced liver disease or who have already progressed to decompensated cirrhosis. examples of previous therapy includes but is not limited to pegylated interferon (pegifn), bulevirtide or lonafarnib. participants with failure to previous therapy with compensated cirrhosis will receive rep 2139-mg (250mg sc qw), tdf (300mg po qd) and pegifn (90ug sc qw) for 48 weeks. participants with decompensated cirrhosis will receive rep 2139-mg (250mg sc qw) and tdf (300mg po qd). during therapy, safety will be monitored weekly and efficacy every 4 weeks. patients who maintain hbsag loss for 6 months following removal of rep 2139-mg and pegifn will be eligible for removal of the remaining tdf therapy.

Eligibility criteria:
inclusion criteria: 1. confirmed hbv or hbv / hdv co-infection. 2. prior failure to pegifn, bulevirtide, or lonafarnib or combinations thereof with advanced fibrosis or compensated cirrhosis. 3. decompensated cirrhosis. 4. willingness to utilize adequate contraception while being treated with rep 2139-mg and for 6 months following the end of rep 2139-mg treatment. exclusion criteria: 1. women with positive serum or urine pregnancy test (minimum sensitivity 25 iu/l or equivalent units of hcg). 2. breast-feeding women.

Keywords: nucleic acid polymer rep 2139-mg hbv hdv cirrhosis functional cure
effect and mechanism of social interaction treatment on asd children

Conditions: ASD

Summary: current study try to find out whether social interaction treatment is effective for asd children. asd children will be divided into three groups, social interaction treatment group, neuronal cognition treatment and routine treatment group. based on excited recognition training treatment effect on the core symptom of adhd by tablet computer, the investigators propose that tablet computer social interaction treatment may induce a significant improvement in ameliorating the social disorder of asd.

appropriate and effective treatment coupled with home training can help asd children restore the ability of language, behavior and learning. however, there is no suitable and effective behavior intervention for home training yet. current study try a 3 months' randomized double-blinded clinical trial to find out whether tablet computer social interaction treatment at home is effective for asd children. 90 3-6 years old asd children will be included and divided into three groups, social interaction treatment group, neuronal cognition treatment and routine treatment group respectively. during the treatment days, children in social interaction treatment group will have 30min social interaction each day for 3 months. children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months. children in routine treatment group will keep the same initial treatment. all asd children are followed up closely. the primary observed indicator is the score of childhood autism rating scale (cars) at the inclusion, one month and 3 month after treatment to evaluate the effect of tablet computer social interaction treatment on asd children.

Eligibility criteria:
inclusion criteria： * patients diagnosed with asd. diagnostic criteria: diagnosed by pediatric psychiatrists in accordance with the criteria in the fifth edition of diagnostic and statistical manual of mental disorders (dsm-v), autism diagnostic observation schedule (ados) and autism diagnostic interview-revised (adi-r) * cars ≥ 34 * agree to sign the informed consent exclusion criteria： * children with abnormal gene and chromosome * children with neurodevelopmental diseases (like epilepsy, schizophrenia) * children with severe sense perception disorder * children with weight over 20kg, with electronic metal products in body unsuited for magnetic resonance imaging
neph-rosis (nephrology in cirrhosis) pilot trial: a trial to treat acute kidney injury among hospitalized cirrhosis patients

Conditions: Acute Kidney Injury; Cirrhosis; Portal Hypertension; Hepatorenal Syndrome; Acute Tubule Necrosis; Prerenal Failure

Summary: the goal of this pilot, randomized, single-blind clinical trial is to estimate the effect size of a high and low mean arterial pressure (map)-target algorithm among cirrhosis patients hospitalized with acute kidney injury. the main aims to answer are: • does an algorithm that has low (\<80 mmhg) and high (≥80) map-targets lead to significant differences in mean arterial pressure? • are there any serious adverse events (e.g., ischemia) in a high blood pressure algorithm as compared to a low blood pressure algorithm? • are there any differences in the incidence of aki reversal in the high v. low map-target groups? participants will be: 1) randomized to a clinical algorithm that will either target a low (\<80 mmhg) or high (≥80 mmhg) map. 2) depending on their group, investigators will titrate commonly used medications to a specific map target. researchers will compare the high and low map-target groups to see if these algorithms lead to significant changes in map, if they have any impact on aki reversal, and if there are any adverse events in the high map-target group.


Eligibility criteria:
inclusion criteria: * hospitalized patients with decompensated cirrhosis, defined as a child-pugh score ≥ 7 * acute kidney injury: a ≥50% increase in scr from an outpatient baseline scr measured 7 to 365 days prior to admission exclusion criteria: 1. patients without a baseline (7 - 365 days prior to aki development) scr measurement; 2. patients who are already on kidney replacement therapy (krt) at the time of enrollment; 3. patients with an oxygen requirement greater than 6l via nasal cannula; 4. patients with a serum creatinine level exceeding 5 mg/dl.

Keywords: pragmatic feasibility
the use of a virtual reality intervention on stigma, empathy and attitudes towards people with psychotic disorders

Conditions: Mental Disorder

Summary: the goal of this clinical trial is to evaluate the effectiveness of a vr intervention on (1) stigma, (2) empathy and (3) attitudes towards those experiencing mental disorders. participants will review a vr intervention, and complete questionnaires at pre-test, post-test and one month follow-up. researchers will compare the vr intervention with a control vr intervention to evaluate the varying effects on stigma, empathy and attitudes towards those experiencing mental disorders.


Eligibility criteria:
inclusion criteria: * participants who are aged at least 21 years old * employed by the institute of mental health as a physician, allied health professional or nurse. * understands english * work directly with patients. exclusion criteria: * unable to use virtual reality interventions due to reasons including motion sickness, disorientation, nausea and vomiting. * history of epilepsy
digital self-management and health coaching for type 2 diabetes - impact on diabetes clinical and wellness indicators

Conditions: Diabetes Mellitus, Type 2

Summary: each subject enrolled in the study will be requested to complete an intake questionnaire including diabetes quality of life questions. the subject will use dario blood glucose monitoring system and will be contacted by a certified diabetes educator (cde) two to three times a month as well as have a direct communication using other communication channels such as mail, chat and text messaging (sms) for lifestyle and diabetes management coaching for a total duration of three months. in the end of study, the subject will complete a diabetes quality of life questionnaire and have a blood test to evaluate its clinical parameters.

this study is designed to assess the effect of digital self-monitoring platform used with the remote support of a health coach on clinical outcomes and diabetes quality of life. study design will be an open-label randomized trial of adults with type 2. patients are recruited through the diabetes and endocrinology consultants center setting. upon randomization to the intervention group, study participants will receive three months diabetes health coaching comprising of: 1. two scheduled phone sessions with a diabetes health coach a month; 2. ongoing dual communication with the coach using digital communication channels such as chat, sms and emails 3. diabetes education, behavior modification, goal setting and reinforcement. the dario app will record participant's glucose measurements and additional information captured by the patient such as medication intake, food and physical activity results. the coach will get access to the patients' app captured information and will intervene ad necessary in the context of the clinical information.

Eligibility criteria:
inclusion criteria: to be eligible to participate in this study, a subject must meet all the following criteria: 1. adults 35 years of age or older 2. diagnosed type 2 diabetes 3. hba1c test taken less than 2 months ago and is equal to or above 8.5% 4. able to read, write and understand english 5. have supported smartphone (see appendix c for the full smartphone list) with internet package for their service provider 6. the subject is able and agrees to sign the informed consent form exclusion criteria: 1. adults with impaired cognition 2. cohabiting with a participant in the study 3. have an underlying medical condition (such as kidney disease, hemoglobin variants, anemia) that may provide misleading a1c levels 4. subject is critically ill 5. subject has an impairment that prevents him/her from following the study procedures 6. subject is not using medication that may interfere with the blood glucose measurement 7. hct level which are outside dario bgms declared range (20%-60%)